Aethlon Medical (NASDAQ:AEMD – Get Free Report) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($2.60) earnings per share for the quarter, topping the consensus estimate of ($2.91) by $0.31, FiscalAI reports.
Aethlon Medical Price Performance
Aethlon Medical stock traded up $0.05 during trading hours on Thursday, reaching $5.58. The stock had a trading volume of 20,694 shares, compared to its average volume of 797,152. The company has a market cap of $3.97 million, a price-to-earnings ratio of -0.16 and a beta of 1.27. The business’s 50 day moving average price is $4.98 and its 200-day moving average price is $7.45. Aethlon Medical has a 52 week low of $1.41 and a 52 week high of $25.66.
Analysts Set New Price Targets
Several brokerages recently issued reports on AEMD. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a report on Saturday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $1.50.
Aethlon Medical Company Profile
Aethlon Medical, Inc. is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles. The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.
Read More
- Five stocks we like better than Aethlon Medical
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
